IRVINE, Calif., June 30, 2021 /PRNewswire/ — Predictive Health Diagnostics Company, Inc. (“PHDC” or “the Company”), a diagnostics platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics to detect diseases with significant unmet medical needs, today announced that its Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, Morningstar Laboratories (“Morningstar”) is experiencing strong gains in in-network provider participation and that the laboratory has achieved accreditation from the College of American Pathologists (CAP).
Predictive Health Diagnostics Company (PRNewsfoto/Predictive Health Diagnostics Company)
“We are pleased to report that Morningstar is demonstrating a strong pattern of success in accelerating and expanding its in-network status over the past several months,” said Douglas S. Harrington, M.D., Executive Chairman of Predictive Health Diagnostics Company, and Morningstar Laboratory Director. “Being part of a broad provider network is important because it makes our diagnostic tests more accessible and affordable to large numbers of physicians and patients. For example, Blue Cross and Blue Shield of Texas recently accepted Morningstar in network. BCBS TX is the largest provider of health benefits in the state, working with approximately 80,000 healthcare practitioners and 500 hospitals, and serving 5 million members in all counties.”
Morningstar’s network of participating providers has expanded significantly, due in large part to accelerating demand and utilization of PHDC’s PULS Cardiac Test™ and DIABETESpredict™ in healthcare settings nationwide. A distribution milestone for PHDC was reached recently with the placement of the 120,000th physician order of the PULS Cardiac Test, a reflection of growing awareness of the unique ability for the specialty diagnostic test to save lives for the more than 120 million Americans afflicted with cardiac disease. PHDC announced the North American launch of its second diagnostic test, DIABETESpredict, earlier this month. These tests are the only ones of their kind, respectively, that can identify asymptomatic patients at risk of a heart attack who are missed by current standard methodologies (PULS Cardiac Test™), and that can identify type 2 diabetes risk before symptoms or abnormal lab results are discovered (DIABETESpredict™).
Commenting on Morningstar’s accreditation by CAP, Harrington explained, “CAP observes a high number of specialty-specific quality standards, and, coupled with our CLIA compliance, shows that our laboratories meet and exceed the highest standards of quality.”
According to the College of American Pathologists, CAP-accredited laboratories around the world demonstrate excellence in patient care and confidence in laboratory practices. To help laboratories maintain high-quality standards for patients, CAP’s accreditation program monitors proficiency testing results for 83 CLIA-regulated analytes, plus more than 300 analytes specially chosen by pathologists for their clinical utility and medical relevance.
About Predictive Health Diagnostics Company
Predictive Health Diagnostics Company (PHDC) is a leading specialty diagnostics development platform company that develops, manufactures, and distributes unique medical tests combining science, technology, and proprietary analytics to detect high-risk diseases with significant unmet medical needs. The Company’s PULS Cardiac Test™, marketed in the U.S., the Middle East, Asia, and Canada, identifies asymptomatic patients at risk of a heart attack who are missed by the current standard of care, and its DIABETESpredict™ test, distributed throughout North America, identifies genetic risk of type 2 diabetes before symptoms or abnormal lab results are discovered, and provides in depth information to those already diagnosed. PHDC’s laboratory information systems use data from multiple sources including proteomics, genetics, metabolics, biochemistry, phenotype, and imaging to address among the most challenging clinical problems. Morningstar Laboratories, a PHDC company, is a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory offering comprehensive and customized services based on Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit PHDC at phdiagnostics.com, Twitter, Facebook, and LinkedIn.
Forward-looking statements are based on our current expectations and assumptions regarding our business, our industry, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.